Endoluminal Drug Delivery

About

INVENTION The novel device for endoluminal drug delivery, unlike the conventional stenting, enables direct localized drug treatment and at the same time reduces rupture of blood vessel wall and enables healing without coil interference. The coils can be coated with drug-loaded biodegradable coating, or can be porous where the pores contain drugs to enable drug or combination of drugs release into aberrant cavities. A Combination of drugs transformed liquid into solid can also be delivered. The solid would further form a seal at the cavity mouth to reduce fluid pressure inside the cavities. Moreover, the device can form bonds with surrounding walls to prevent dislodgement. The devices can be fabricated with, but not limited to, biodegradable or bio-soluble materials, which can completely dissolve and further allow the cavity to shrink. The combinations of drugs delivered by the device can strengthen the walls surrounding the cavities. MARKET OPPORTUNITY Aberrant cavities such as aneurysms can be fatal. According to the US National Institute of Neurological Disorders and Stroke, there are 10 cases of aneurysm ruptures in every 100,000 people each year. Although it can be treated in open surgeries, it is invasive and long recovery is required. The existing technology for endoluminal surgeries provides an option with shorter recovery period; nevertheless, topically drug delivery to the cavities is unavailable. Conventional stenting surgically alters the structure of or fluid dynamics in blood vessels and aberrant cavities without providing topical drug treatment. This invention not only increases the survival rate of aberrant cavities patients but also improves their quality of life. Key Benefits Endoluminal topical delivery of drugs to directly to aberrant cavity Prevention of aneurysm rupture Bio-soluble structure Simple operation